UNSPSC 51321706: Atorvastatin calcium

This classification denotes a hmg-coa reductase inhibitor with the molecular formula 2C33H34FN2O5.Ca.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48A5M73Z4Q, chemically known as 1h-pyrrole-1-heptanoic acid, beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (r-(r*,r*))- but more generally known as atorvastatin calcium, which bears US NIH Compound Identifier 60822.

UNSPSC 51321706 Atorvastatin calcium is a Commodity code covering a single active pharmaceutical ingredient—atorvastatin calcium, a statin medication for cholesterol management—that state and local governments procure primarily through emergency medical services and public health programs. Recent solicitations show atorvastatin itself does not appear as a line item in current opportunities; instead, state and local buyers are acquiring broader pharmaceutical portfolios that may include this drug as part of multi-source generic medication contracts or advanced life support medication bundles. The issuing bodies soliciting under this code tier are diverse, ranging from municipal fire-rescue departments (City of Tampa) to state health agencies (Texas HHS Commission) to multistate cooperative purchasing alliances serving state departments and local facilities (Minnesota Multistate Cooperative Purchasing Alliance). The Tampa Fire Rescue solicitation illustrates the emergency-services use case—acquisition of life-support medications for field deployment—while the MMCAP RFP demonstrates the institutional pharmacy procurement channel, where state and local governments contract with manufacturers for generic multi-source drugs distributed across health facilities.

Recent activity is concentrated in Florida and Minnesota, with exploratory procurement activity in Texas. The City of Tampa's Purchasing Department issued Bid No. 26P00188 on April 24, 2026, seeking Advanced Life Support Medications (response deadline April 8, 2026; estimated contract value $40,000) through sealed bidding via the OpenGov eProcurement Portal, with a one-year term and two optional renewal periods. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, posted RFP S1070000015802 on January 20, 2026 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities including Oregon, with a two-year base term. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence on direct-to-manufacturer prescription programs as a preliminary information-gathering phase before formal competitive solicitation. Atorvastatin as a discrete line item does not surface in these recent opportunities; companies pursuing this code should monitor cooperative purchasing RFPs and institutional pharmacy contracts where generic statins are bundled with broader medication portfolios.